Biosite POC (point-of-care) D-Dimer test:
This article was originally published in Clinica
Executive Summary
Biosite has received US FDA 510(k) clearance to sell its point-of-care (POC) Triage D-Dimer test for helping doctors assess patients suspected of having thromboembolic events, including pulmonary embolism (PE). Portable and easy-to-use, the test can be used in the emergency room (ER) or at the patient's bedside, said the San Diego, California firm. The company added that a recent study showed that a POC clinical protocol for assessing PE, using an available latex-agglutination test for D-Dimer, doubled the number of patients evaluated for the condition and decreased length of stay in the ER, without increasing the need for vascular imaging. At least 650,000 cases of PE occur annually in the US.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.